LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 71-82.e12

  Zambrowicz, Brian ^a   Lapuerta, Pablo ^a   Strumph, Paul ^a   Banks, Phillip ^a   Wilson, Alan ^a   Ogbaa, Ike ^a   Sands, Arthur ^a   Powell, David ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Fasting plasma glucose; LX4211; Pharmacokinetics; Postprandial glucose; Renal impairment; SGLT1; SGLT2; Urinary glucose excretion

Indexed keywords

CREATINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PLACEBO; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPOGLYCEMIA; JOINT INJURY; LACERATION; LUNG ABSCESS; MALE; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; VOMITING; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSURIA; KIDNEY FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; POSTPRANDIAL STATE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCOSIDES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RENAL INSUFFICIENCY;

EID: 84920772335     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.10.026     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
2. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-2539.
3. Koro CE, Lee BH, Bowlin SJ. Anti-diabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608-2617.
4. Vupputuri S, Kimes TM, Calloway MO, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications. 2014;28:10-16.
5. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673-682.
6. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
7. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58:1651-1658.
8. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53:2312-2319.
9. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302-308.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;13:977-986.
11. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;13:1703-1720.
12. UK Prospective Diabetes Study (UKPDS) Group (UKPDS 33). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
13. The Epidemiology of Diabetes Interventions and Complications (EDIC) study. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA. 2003;290:2159-2167.
14. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
15. Ismail-Beigi F, Craven T, Banerji MA, et al, and ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-430.
16. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013;9:147-153.
17. Nogueira C, Souto SB, Vinha E, et al. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones (Athens). 2013;12:483-494.
18. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(Suppl 2):S12-S154.
19. Chen SY, Siu K, Kovacs B, et al. Clinical and economic outcomes associated with National Kidney Foundation guideline concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Curr Med Res Opin. 2012;28:493-501.
20. Chen SY, Lee YC, Alas V, et al. Outcomes associated with concordance of oral antidiabetic drug treatments to prescribing information in patients with type 2 diabetes mellitus and chronic kidney disease. J Med Econ. 2013;16:586-595.
21. Chen SY, Lee YC, Alas V, et al. Outcomes associated with nonconcordance to National Kidney Foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease. Endocr Pract. 2014;20:221-231.
22. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453-467.
23. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158-169.
24. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273-285 e7.
25. Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-259.
26. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor,on postprandial glucose, insulin, glucagon-lie peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther. 2013;35:1162-1173 e8.
27. Rosenstock JL, Zambrowicz B, Ogbaa I, et al. LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, lowers HbA1c and improves cardiovascular risk factors in patients with type 2 diabetes. Published online before print September 11, 2014.
28. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
29. Yale JF, Bakris G, Cariou B, et al. Ef ficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
30. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384.
31. Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110:4410-4415.
32. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207-1216.
33. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2011. Academic Medical Center, Department of Medical Informatics. Amsterdam, the Netherlands; 2013.
34. Muntner P, Anderson A, Charleston J, et al, and Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441-451.